Key result
Intracoronary aspirin reduces peak reactive hyperemia flow ~18% in preclinical models.
Why the study?
The effects of intracoronary aspirin on coronary blood flow and reactive hyperemia were not fully characterized in a controlled experimental setting.
Does intracoronary aspirin reduce coronary blood flow and reactive hyperemia in a canine model?
Population
18 closed-chest anesthetized dogs with cannulated left circumflex coronary artery
Comparison
Intracoronary aspirin at doses of 5, 10, 20, and 25 mg versus baseline
Design
Preclinical experimental study
Authors
Loading...
May warrant caution with intracoronary aspirin; leaves open effects on human coronary reactivity.
Does intracoronary aspirin reduce coronary blood flow and reactive hyperemia in a canine model?
Absolute Event Rate: 1.75% vs 2.13%
p-value: p=<0.005
Intracoronary aspirin increases coronary arterial resistance and restricts maximal dilating capacity in a canine model, likely via inhibition of prostacyclin synthesis.
Miyajima et al. (1989) studied this question. Intracoronary aspirin vs. Baseline/Control was evaluated on Mean peak flow ratio (reactive hyperemia following 15-second coronary occlusion) (p=<0.005). Intracoronary aspirin reduced the mean peak flow ratio of reactive hyperemia from 2.13 to 1.75 (p<0.005) in anesthetized dogs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: